INTELLIGENT MICROSCOPE WORKSTATION FOR CANCER DIAGNOSIS

本SBIR第一阶段提案由病理成像公司提交。 (PIC)根据1971年国家癌症法案的精神， 卫生和人类服务部（当时的卫生、教育和福利部） 加快研究成果转化为 广泛应用。“1984-1990年间， 大学和南加州大学）使用18万美元 库尔特生物医学研究机器人显微镜，diff 3/50，连接到一个 80 000美元Interdata 3230型计算机，根据一系列 NIH赠款累计资助超过100万美元， 滤泡性淋巴瘤亚型的智能性能。 所得 系统，当与病理学家的专家视觉技能合作时， 定位卵泡，实现的性能远远超过 机器人或病理学家单独行动。 与此同时，PIC资助了 减少了一台价值5 000美元的电脑摄像机， 具有与个人计算机的网络接口的数字显微镜。 使用 Kensal Consulting的这款相机和基于PC的图像分析软件 （图森）在一个与病理学系的联合项目中， 得克萨斯州，PIC再现了CMU/USC在一天内取得的成果。 以来 患者样本太小，无法得出统计学结论， 因此，本建议的目的是要求提供资金， 100-200例患者的确定性研究（是CMU/USC研究的5倍） 并同时确定算法环境的鲁棒性 关于分辨率、放大率、颜色等。 第一阶段的研究将是减少实践和彻底测试 CMU/USC癌症诊断，可以商业化生产和销售 在第三阶段期间在全国范围内广泛使用，价格为15，000美元，或 少一个单位。

This SBIR Phase I proposal is submitted by the Pathology Imaging Corp. (PIC) in the spirit of the National Cancer Act of 1971 which gave the Dept. of Health and Human Services (then Health, Education, and Welfare) the responsibility to "speed the translation of research results into widespread application." During 1984-1990 academia (Carnegie Mellon University and the University of Southern California) using the $180,000 Coulter Biomedical Research robot microscope, the diff3/50, interfaced to a $80,000 Interdata model 3230 computer, conducted research under a series of NIH grants cumulatively funded at over one million dollars which achieved intelligent performance in subtyping follicular lymphomas. The resulting system, when teamed with the expert visual skills of the pathologist in locating follicles, achieved performance far exceeding that of either the robot or the pathologist acting alone. At the same time PIC funded the reduction to practice of a proprietory $5,000 computerized camera for digital microscopy having a network interface to personal computers. Using this camera and PC-based image analysis software by Kensal Consulting (Tucson) in a joint project with the Department of Pathology, University of Texas, PIC reproduced IN ONE DAY the results achieved by CMU/USC. Since the patient sample was too small to draw statistical conclusions, it is therefore the purpose of this proposal to request funding to conduct a definitive study of 100-200 patients (five times that of the CMU/USC study) and simultaneously determine the robustness of the algorithmic environment with regard to resolution, magnification, color, etc. The aim of this Phase I research would be to reduce to practice and exhaustively test the CMU/USC cancer diagnosis which could be manufactured commercially and sold for widespread use nationwide during Phase III at a price of $15,000 or less per unit.